Septerna To Present At TD Cowen 45Th Annual Health Care Conference

2025-02-26 08:16:20

(MENAFN- GlobeNewsWire - Nasdaq) SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the TD Cowen 45^th Annual Health Care Conference on Wednesday, March 5, 2025, at 10:30 a.m. ET in Boston.

About Septerna
Septerna, Inc. is a biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex PlatformTM. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of oral small molecule product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Septerna was launched by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural biology, and pharmacology of GPCRs. For more information, please visit .

Investor Contact:
Renee Leck
THRUST Strategic Communications
...

MENAFN26022025004107003653ID1109252142

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.